Isis Pharmaceuticals Inc., of Carlsbad, Calif., surged 13.3 percent on news Biogen Idec Inc., based in Weston, will make an upfront payment of $100 million as part of a six-year collaboration to develop drugs for neurological disorders. Isis’ specialty is antisense technology, which can activate genes or silence a genetic mutation to help treat disorders. Biogen Idec gets exclusive rights to the technology, the companies said. Isis is also eligible to receive milestone payments, license fees, and royalty payments. Biogen rose 1.6 percent.